Drug
MK 6916
MK 6916: highest development phase Phase 2, developed by Merck. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| MK-6916 NCT07862595 | Phase 2 | Pain Management |
| MK-6916 NCT07922174 | Phase 1 | Renal Impairment |
Latest
No recent events.
Follow MK 6916 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.